Jiangsu Simcere Pharmaceutical patents new MAP4K1 inhibitors for cancer

Nov. 24, 2022

Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has disclosed alkyne compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Dec. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 9, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

ASH 2025: Tec-dara shines on ‘functional cure’ Majestec-3 MM data

BioWorld

Impressive results of a potential second-line combination treatment for multiple myeloma from the Majestec-3 trial of teclistamab plus daratumumab raised eyebrows...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...